Events

Wired Health w/ Joanna Shields

Join BenevolentAI’s CEO Joanna Shields at Wired Health where she will be speaking about forging new frontiers in drug discovery by uniting human and artificial intelligence.

While the past year has reinforced the fragility of human health, it has also demonstrated the value of leveraging AI to solve some of healthcare's greatest challenges. The speech will draw on BenevolentAI's pioneering work and powerful collaborations with leading pharma companies to further illustrate where AI has had a proven impact, both during the pandemic and in drug discovery more generally. Joanna will reflect on lessons learned from her leadership experience in big tech and government to lay out her vision for the future of scientific discovery: where human and artificial intelligence are united to solve complex pharmaceutical puzzles, unlock the value of vast data sets, and deliver new life-changing treatments to patients in need.


Register here →


Joanna Shields

Chief Executive Officer

Joanna is a tech industry veteran with over 25 years experience building and scaling global companies including Facebook, Bebo, Aol, Google, Real Networks and Efi. Prior to joining Benevolent AI, she served in UK Government as Under Secretary of State and Minister for Internet Safety & Security, Digital Economy Adviser and Chair and CEO of TechCityUK. Joanna is passionate about creating responsible technology that benefits humanity. She is a leading advocate for children's rights and safety online and founder of the WeProtect Global Alliance, and a Life Peer of the House of Lords.

More Posts

You Might Also Like

News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021
News
BenevolentAI named as one of Fierce Medtech’s Fierce 15 of 2020
BenevolentAI was selected as one of the most promising private companies in the industry by Fierce Medtech in its Fierce 15 2020 list.
Mar 8, 2021
Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021
News
BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
BenevolentAI and AstraZeneca hit collaboration milestone with an AI-generated CKD target from the partnership entering AstraZeneca’s portfolio.
Jan 27, 2021
News
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Jan 15, 2021